NATIONAL DIABETIC SCREENING PROGRAMME

NATIONAL DIABETIC SCREENING PROGRAMME

Kowa Optimed has announced that its latest innovation, the Nonmyd WX 3D, has been approved for the English National Screening Programme for Diabetic Retinopathy in the UK. With over five million people expected to have diabetes in the UK by 2025, and with diabetic retinopathy being the main cause of blindness in the 16-65 year-old age group, the National Screening Programme aims to reduce the risk of sight loss by offering annual screening to diabetic patients for prompt identification and effective treatment of sight-threatening retinopathies.
www.kowa.eu/medicals

Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...